{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:03:01Z","timestamp":1778720581936,"version":"3.51.4"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31370849"],"award-info":[{"award-number":["31370849"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670531"],"award-info":[{"award-number":["81670531"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ijbiomac.2023.126874","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T02:12:12Z","timestamp":1694484732000},"page":"126874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P3","title":["Effects of the glycosylation of the receptor binding domain (RBD dimer)-based Covid-19 vaccine (ZF2001) on its humoral immunogenicity and immunoreactivity"],"prefix":"10.1016","volume":"253","author":[{"given":"Xueqing","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lulu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yirong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zelan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenglong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Can","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anhui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.ijbiomac.2023.126874_bb0005","doi-asserted-by":"crossref","first-page":"12904","DOI":"10.1002\/anie.202100543","article-title":"Synthetic homogeneous glycoforms of the SARS-CoV-2 spike receptor-binding domain reveals different binding profiles of monoclonal antibodies","volume":"60","author":"Ye","year":"2021","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"8","key":"10.1016\/j.ijbiomac.2023.126874_bb0010","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"8","key":"10.1016\/j.ijbiomac.2023.126874_bb0015","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41563-020-0746-0","article-title":"Next-generation vaccine platforms for COVID-19","volume":"19","author":"van Riel","year":"2020","journal-title":"Nat. Mater."},{"issue":"11","key":"10.1016\/j.ijbiomac.2023.126874_bb0020","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/s41578-020-00247-y","article-title":"A materials-science perspective on tackling COVID-19","volume":"5","author":"Tang","year":"2020","journal-title":"Nat. Rev. Mater."},{"issue":"10","key":"10.1016\/j.ijbiomac.2023.126874_bb0025","doi-asserted-by":"crossref","first-page":"12522","DOI":"10.1021\/acsnano.0c07197","article-title":"COVID-19 vaccine frontrunners and their nanotechnology design","volume":"14","author":"Chung","year":"2020","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.126874_bb0030","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.matt.2020.08.005","article-title":"Why go NANO on COVID-19 pandemic?","volume":"3","author":"Talebian","year":"2020","journal-title":"Matter"},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.126874_bb0035","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.cell.2020.09.018","article-title":"Molecular architecture of the SARS-CoV-2 virus","volume":"183","author":"Yao","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2023.126874_bb0040","doi-asserted-by":"crossref","first-page":"701501","DOI":"10.3389\/fimmu.2021.701501","article-title":"SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants","volume":"12","author":"Martinez-Flores","year":"2021","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.ijbiomac.2023.126874_bb0045","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S2213-2600(22)00131-X","article-title":"Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"10","author":"Zhu","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"8","key":"10.1016\/j.ijbiomac.2023.126874_bb0050","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7830","key":"10.1016\/j.ijbiomac.2023.126874_bb0055","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2023.126874_bb0060","series-title":"SARS-CoV-2 Ferritin Nanoparticle Vaccines Elicit Broad SARS Coronavirus Immunogenicity","author":"Joyce","year":"2021"},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.126874_bb0065","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"6483","key":"10.1016\/j.ijbiomac.2023.126874_bb0070","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ijbiomac.2023.126874_bb0075","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/glycob\/cwaa101","article-title":"Comprehensive characterization of N- and O- glycosylation of SARS-CoV-2 human receptor angiotensin converting enzyme 2","volume":"31","author":"Shajahan","year":"2021","journal-title":"Glycobiology"},{"key":"10.1016\/j.ijbiomac.2023.126874_bb0080","first-page":"107","article-title":"A vaccine based on the receptor-binding domain of the spike protein expressed in glycoengineered Pichia pastoris targeting SARS-CoV-2 stimulates neutralizing and protective antibody responses","volume":"13","author":"Liu","year":"2022","journal-title":"Engineering (Beijing)"},{"issue":"17","key":"10.1016\/j.ijbiomac.2023.126874_bb0085","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1021\/acs.analchem.1c00893","article-title":"Structural and functional characterization of SARS-CoV-2 RBD domains produced in mammalian cells","volume":"93","author":"Gst\u00f6ttner","year":"2021","journal-title":"Anal. Chem."},{"issue":"6501","key":"10.1016\/j.ijbiomac.2023.126874_bb0090","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1126\/science.abb9983","article-title":"Site-specific glycan analysis of the SARS-CoV-2 spike","volume":"369","author":"Watanabe","year":"2020","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.ijbiomac.2023.126874_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237295","article-title":"Development and simulation of fully glycosylated molecular models of ACE2-Fc fusion proteins and their interaction with the SARS-CoV-2 spike protein binding domain","volume":"15","author":"Bernardi","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2023.126874_bb0100","series-title":"Beyond Shielding: The Roles of Glycans in SARS-CoV-2 Spike Protein","author":"Casalino","year":"2020"},{"issue":"12","key":"10.1016\/j.ijbiomac.2023.126874_bb0105","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/glycob\/cwaa042","article-title":"Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2","volume":"30","author":"Shajahan","year":"2020","journal-title":"Glycobiology"},{"issue":"4","key":"10.1016\/j.ijbiomac.2023.126874_bb0110","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.chom.2020.08.004","article-title":"Virus-receptor interactions of glycosylated SARS-CoV-2 spike and human ACE2 receptor","volume":"28","author":"Zhao","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"47","key":"10.1016\/j.ijbiomac.2023.126874_bb0115","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1016\/j.vaccine.2020.09.061","article-title":"Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement","volume":"38","author":"Chen","year":"2020","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.126874_bb0120","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4161\/hv.27464","article-title":"Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate","volume":"10","author":"Chen","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"issue":"8","key":"10.1016\/j.ijbiomac.2023.126874_bb0125","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.xphs.2017.04.037","article-title":"Optimization of the production process and characterization of the yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1), a SARS vaccine candidate","volume":"106","author":"Chen","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2023.126874_bb0130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbrc.2021.09.053","article-title":"SARS-CoV-2 spike protein receptor-binding domain N-glycans facilitate viral internalization in respiratory epithelial cells","volume":"579","author":"Zheng","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.126874_bb0135","doi-asserted-by":"crossref","first-page":"15162","DOI":"10.1038\/s41598-021-94602-w","article-title":"S494 O-glycosylation site on the SARS-CoV-2 RBD affects the virus affinity to ACE2 and its infectivity; a molecular dynamics study","volume":"11","author":"Rahnama","year":"2021","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.126874_bb0140","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","article-title":"A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS","volume":"182","author":"Dai","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.126874_bb0145","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1080\/22221751.2022.2056524","article-title":"A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates","volume":"11","author":"An","year":"2022","journal-title":"Emerg. Microbes Infect."},{"issue":"5","key":"10.1016\/j.ijbiomac.2023.126874_bb0150","doi-asserted-by":"crossref","DOI":"10.1038\/s41559-021-01407-1","article-title":"ACE2 receptor usage reveals variation in susceptibility to SARS-CoV and SARS-CoV-2 infection among bat species","volume":"5","author":"Yan","year":"2021","journal-title":"Nat. Ecol. Evol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.126874_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"7815","key":"10.1016\/j.ijbiomac.2023.126874_bb0160","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.ijbiomac.2023.126874_bb0165","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.3748\/wjg.v20.i18.5474","article-title":"Use of lectin microarray to differentiate gastric cancer from gastric ulcer","volume":"20","author":"Huang","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"16","key":"10.1016\/j.ijbiomac.2023.126874_bb0170","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.7150\/jca.43806","article-title":"Identification of LCA-binding glycans as a novel biomarker for esophageal cancer metastasis using a lectin array-based strategy","volume":"11","author":"Xia","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.ijbiomac.2023.126874_bb0175","doi-asserted-by":"crossref","first-page":"123207","DOI":"10.1016\/j.ijbiomac.2023.123207","article-title":"Identification of a type II LacNAc specific binding lectin CMRBL from Cordyceps militaris","volume":"230","author":"Liu","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"issue":"12","key":"10.1016\/j.ijbiomac.2023.126874_bb0180","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1021\/pr500414q","article-title":"Fc gamma receptor glycosylation modulates the binding of IgG glycoforms: a requirement for stable antibody interactions","volume":"13","author":"Hayes","year":"2014","journal-title":"J. Proteome Res."},{"issue":"30","key":"10.1016\/j.ijbiomac.2023.126874_bb0185","doi-asserted-by":"crossref","first-page":"26733","DOI":"10.1074\/jbc.M202069200","article-title":"Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity","volume":"277","author":"Shields","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.126874_bb0190","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ccell.2019.06.008","article-title":"Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1\/PD-L1 therapeutic efficacy","volume":"36","author":"Lee","year":"2019","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.ijbiomac.2023.126874_bb0195","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/glycob\/cwab032","article-title":"The role of cell surface sialic acids for SARS-CoV-2 infection","volume":"31","author":"Sun","year":"2021","journal-title":"Glycobiology"},{"key":"10.1016\/j.ijbiomac.2023.126874_bb0200","first-page":"118(19)","article-title":"Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike","author":"Mehdipour","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2023.126874_bb0205","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.73641","article-title":"Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor","volume":"10","author":"Capraz","year":"2021","journal-title":"Elife"},{"issue":"5","key":"10.1016\/j.ijbiomac.2023.126874_bb0210","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","article-title":"The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity","volume":"182","author":"Li","year":"2020","journal-title":"Cell"},{"issue":"7819","key":"10.1016\/j.ijbiomac.2023.126874_bb0215","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"issue":"45","key":"10.1016\/j.ijbiomac.2023.126874_bb0220","doi-asserted-by":"crossref","first-page":"34610","DOI":"10.1074\/jbc.M603275200","article-title":"Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R","volume":"281","author":"Hwang","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.ijbiomac.2023.126874_bb0225","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41594-020-0480-y","article-title":"Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient","volume":"27","author":"Zhou","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"12","key":"10.1016\/j.ijbiomac.2023.126874_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010203","article-title":"Cross-reactive and mono-reactive SARS-CoV-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals","volume":"17","author":"Johansson","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ijbiomac.2023.126874_bb0235","series-title":"Glycoinformatics Approach for Identifying Target Positions to Inhibit Initial Binding of SARS-CoV-2 S1 Protein to the Host Cell","author":"Uslupehlivan","year":"2020"},{"issue":"10","key":"10.1016\/j.ijbiomac.2023.126874_bb0240","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1021\/acscentsci.0c01056","article-title":"Beyond shielding: the roles of Glycans in the SARS-CoV-2 spike protein","volume":"6","author":"Casalino","year":"2020","journal-title":"ACS Cent. Sci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.126874_bb0245","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev.biochem.69.1.69","article-title":"Protein glucosylation and its role in protein folding","volume":"69","author":"Parodi","year":"2000","journal-title":"Annu. Rev. Biochem."},{"issue":"4","key":"10.1016\/j.ijbiomac.2023.126874_bb0250","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/glycob\/cwaa091","article-title":"The iminosugars celgosivir, castanospermine and UV-4 inhibit SARS-CoV-2 replication","volume":"31","author":"Clarke","year":"2021","journal-title":"Glycobiology"},{"issue":"4","key":"10.1016\/j.ijbiomac.2023.126874_bb0255","doi-asserted-by":"crossref","first-page":"166762","DOI":"10.1016\/j.jmb.2020.166762","article-title":"Subtle influence of ACE2 glycan processing on SARS-CoV-2 recognition","volume":"433","author":"Allen","year":"2021","journal-title":"J. Mol. Biol."},{"issue":"7807","key":"10.1016\/j.ijbiomac.2023.126874_bb0260","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"issue":"6508","key":"10.1016\/j.ijbiomac.2023.126874_bb0265","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc0870","article-title":"Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2","volume":"369","author":"Chan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2023.126874_bb0270","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.61552","article-title":"Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration","volume":"9","author":"Yang","year":"2020","journal-title":"Elife"},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.126874_bb0275","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/glycob\/cwac077","article-title":"Structural remodeling of SARS-CoV-2 spike protein glycans reveals the regulatory roles in receptor binding affinity","volume":"33","author":"Hsu","year":"2023","journal-title":"Glycobiology"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813023037716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813023037716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:28:29Z","timestamp":1758882509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813023037716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":55,"alternative-id":["S0141813023037716"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.126874","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of the glycosylation of the receptor binding domain (RBD dimer)-based Covid-19 vaccine (ZF2001) on its humoral immunogenicity and immunoreactivity","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.126874","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"126874"}}